In summary, ACON will build a broad dataset to serve as a platform to revise and tailor acute ON treatment recommendations, improve the differential diagnoses between neuroimmunological disease entities, and identify determinants of disease progression and QoL in subjects after inaugural MS-ON, AQP4-IgG+ON, and MOG-IgG+ON. The gene discussed is MOG; the disease is myeloid sarcoma.